Navigation Links
Daiichi Sankyo And Coherus BioSciences Establish Strategic Collaboration To Develop And Commercialize Biosimilar Candidates
Date:5/7/2012

acted as the exclusive advisor to Coherus BioSciences in this licensing partnership with Daiichi Sankyo.

About Coherus BioSciences

Coherus BioSciences is an emerging biopharmaceutical company headquartered in the San Francisco Bay Area with an entirely new model for developing safe, high-quality biosimilar therapeutics.  Founded in 2010, Coherus already has formed global partnerships with top tier pharma and filled the pipeline with five product candidates focused on treating oncology and inflammatory diseases.  Led by a group of early biotech pioneers, Coherus has reinvented the entire business of developing biologic medicines, from concept to commercialization, so that more patients around the world can have greater access to quality therapeutics. For additional information, please visit www.coherus.com.

About Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit www.daiichisankyo.com.

Contact: Maureen Lopez
Coherus BioSciences
Phone Number 1-800-794-5434

Media contact for Daiichi Sankyo Co. Ltd.: +81-3-6225-1126


'/>"/>
SOURCE Coherus BioSciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB
2. Daiichi Sankyo, Inc. Names Dr. Jay Feingold Vice President, Medical Affairs
3. DAIICHI SANKYO EUROPE GmbH Selects DATATRAK eClinical™ for Pan-European Systolic Hypertension Study
4. Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom
5. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
6. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
7. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
8. Milestone Biosciences, LLC Further Strengthens Executive Management Team
9. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
10. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
11. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 A study has been launched to ... 1 track could help to tackle the problem of obesity. ... (a GP surgery based in Stowmarket) and academics at University ... Telemetry technology, which is inspired by equipment used to ...
(Date:1/15/2014)... January 15, 2014 2013 was a ... Brain State Technologies®. They saw continued independent research led ... who were awarded a $1 million grant from the ... “Brain and Behavior” a peer reviewed journal, Amy Grant ...
(Date:1/14/2014)... Carahsoft and CDS Federal Services have scheduled a ... EST (11am PST), “Natural Language Processing: Converting Raw Data ... can turn raw, heterogeneous data into actionable knowledge to ... webinar will last approximately one hour. , Synopsis: Big ...
(Date:1/14/2014)... Jan. 14, 2014 The largest international professional ... plants and therapeutic derivatives thereof has endorsed an ... researchers about the challenges of adulterated herb and ... The Society for Medicinal Plant ...
Breaking Biology Technology:Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8
... June 13, 2011 K-V Pharmaceutical Company (the "Company") (NYSE: ... for the fiscal year ended March 31, 2011 with the ... be holding an investor conference call today at 4:30 p.m. ... a general update on other company matters. Participants can listen ...
... 2011 Cell Therapeutics, Inc. ("CTI") (NASDAQ: CTICD and MTA: ... list of preliminary additions to the Russell 3000® Index and ... 2011 at www.russell.com .  Russell Investments will finalize the ... on June 24, 2011. "We are very ...
... 10, 2011 /PRNewswire-Asia-FirstCall/ -- China Cord Blood Corporation (NYSE: ... of cord blood collection, laboratory testing, hematopoietic stem cell processing, ... results for the fourth quarter and fiscal year of 2011, ... Quarter of Fiscal 2011 Highlights Revenue in ...
Cached Biology Technology:K-V Pharmaceutical Company Announces Filing of Fiscal 2011 Form 10-K and Schedules Investor Conference Call 2K-V Pharmaceutical Company Announces Filing of Fiscal 2011 Form 10-K and Schedules Investor Conference Call 3K-V Pharmaceutical Company Announces Filing of Fiscal 2011 Form 10-K and Schedules Investor Conference Call 4K-V Pharmaceutical Company Announces Filing of Fiscal 2011 Form 10-K and Schedules Investor Conference Call 5K-V Pharmaceutical Company Announces Filing of Fiscal 2011 Form 10-K and Schedules Investor Conference Call 6K-V Pharmaceutical Company Announces Filing of Fiscal 2011 Form 10-K and Schedules Investor Conference Call 7Cell Therapeutics on Preliminary List of Additions to Russell 3000® Index and Russell Global Index 2Cell Therapeutics on Preliminary List of Additions to Russell 3000® Index and Russell Global Index 3China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 2China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 3China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 4China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 5China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 6China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 7China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 8China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 9China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 10
(Date:4/22/2014)... not only on weight loss but also on diabetes ... University of Cincinnati have shown that the health benefits ... size but by increased levels of bile acids in ... indicate that bile acids could be a new target ... the Sahlgrenska Academy has demonstrated that obesity surgery is ...
(Date:4/21/2014)... 2014 Performing brain research that can one day ... Houston (UH) junior Khanh (Kate) Nguyen has been recognized ... double major in mathematics and physics, Nguyen is among ... , One of the most prestigious awards available ... sophomore and junior students majoring in mathematics, the natural ...
(Date:4/21/2014)... predict which drug candidates offer the greatest potential has ... drug-like molecules and the amino acids of proteins vary ... cunningly managed to develop a method that has proven ... class of human target proteins for drugs are the ... per cent of all drugs on the market. These ...
Breaking Biology News(10 mins):Researchers identify a mechanism linking bariatric surgery to health benefits 2UH student named Goldwater Scholar, 2 more receive honorable mention 2UH student named Goldwater Scholar, 2 more receive honorable mention 3UH student named Goldwater Scholar, 2 more receive honorable mention 4Simulating in tiny steps gave birth to long-sought-after method 2
... Gent - VIB/UGent researchers have unveiled a mechanism that can ... For years, improving drought tolerance has been a major aim ... extreme drought stress. However, translating this research to the field ... in Nature Biotechnology and the Plant Cell ...
... the brain that uses hearing to determine sound location is ... a new study by a team of researchers from Virginia ... These findings propose a new theory for cross-modal plasticity: ... maintaining the original function of the brain region. ...
... Richmond, Va. (May 10, 2011) Cancer researchers ... for advanced prostate cancer after effectively combining an ... vivo using novel ultrasound-targeted microbubble-destruction (UTMD) technology. The ... University Massey Cancer Center, VCU Institute of Molecular ...
Cached Biology News:Drought tolerance in crops: Shutting down the plant's growth inhibition under mild stress 2For hearing parts of brain, deafness reorganizes sensory inputs, not behavioral function 2Microbubble-delivered combination therapy eradicates prostate cancer in vivo 2
... between the various commercial and lab-prepared glass ... the length and GC content of the ... protocol employed all influence the optimal hybridization ... all the different variables to consider, it ...
... Gel Stain combo offers these benefits: ... separately Offers a safer ... Eliminates risks to yourself, the environment and ... 100 bp to >30 kb. UltraPure Agarose is a ...
This is a PYREX replacement Allihn condenser with a 34/45 inner joint on the bottom for the No. CLS3840-S 125mL extractor system. The tubulation O.D. on the condenser is 10mm....
... 400 unique human proteins on a ... proteins, all extracellular proteins (EP) according ... in quadruplicate for high-quality results. Additional ... layout guarantee high validity and reproducibility., ...
Biology Products: